SCHEMBL4649804

SCHEMBL4649804

O[C@@H]1CC[N@@]2CCC[C@@H]1C2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.36
▸ MAN2B1 O00754 1/20 0.34
▸ SLC18A3 Q16572 2/20 0.33
▸ CHRM2 P08172 4/20 0.31
▸ CHRM1 P11229 2/20 0.31
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ CHRM4 P08173 1/20 0.31
▸ CHRM5 P08912 1/20 0.31
▸ CHRM3 P20309 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ GAA P10253 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ NGLY1 Q96IV0 1/20 0.31
▸ GBA2 Q9HCG7 1/20 0.31
▸ GBA1 P04062 1/20 0.31
▸ GANAB Q14697 1/20 0.31
▸ CA12 O43570 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12205442 1.00 CHRNA7 (0.36) CHRNA7MAN2B1SLC18A3CHRM2CHRM1
SCHEMBL412996 1.00 CHRNA7 (0.36) CHRNA7MAN2B1SLC18A3CHRM2CHRM1
SCHEMBL412997 1.00 CHRNA7 (0.36) CHRNA7MAN2B1SLC18A3CHRM2CHRM1
SCHEMBL3965421 1.00 CHRNA7 (0.36) CHRNA7MAN2B1SLC18A3CHRM2CHRM1
SCHEMBL15451780 0.91 CHRNA7 (0.41) CHRNA7MAN2B1SLC18A3CHRM2CHRM1
SCHEMBL11230330 0.87 — —
SCHEMBL8758466 0.83 — —
SCHEMBL4528256 0.83 — —
SCHEMBL8758623 0.83 — —
SCHEMBL13412394 0.76 SLC18A3 (0.38) CHRNA7MAN2B1SLC18A3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966209-A1 [ 1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS. Novartis AG (CH) 2008-09-10 — — EP disclosed
WO-2007068476-A1 [ (1H- INDOL- 5 -YL) -HETEROARYLOXY] - (1-AZA-BICYCLO [3.3.1] NONANES AS CHOLINERGIC LIGANDS OF THE N-ACHR FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENRATIVE DISORDERS. NOVARTIS AG (CH) 2007-06-21 — — WO disclosed
Send feedback